Increased expression of p53 with APR-246 (eprenetapopt) reprograms tumor-associated macrophages to promote the efficacy of immune checkpoint blockade

Expression of genes in sorted CD4, CD8 and non-T CD45 cells isolated from TME of B16 tumors in wildtype B6, APR-246 treated wildtype B6 and Super p53 mice. mice bearing B16 tumors were implanted in super p53 or WT mice. WT mice were treated with vehicle or APR-246 starting day 7 for 6 days and single cell suspensions of the tumors were obtained and antibody stained for CD45, CD8. CD4 and live/dead. CD45+ CD8+, CD45+CD8+ and CD45+CD4-CD8- sorted and RNA was extracted with the PAXgene RNA kit and purified in accordance with the manufacturer’s protocols. RNA was assessed with the Agilent BioAnalyzer for quantity and quality.